Replies to post #111380 on Biotech Values

[acgood]

My sense of the amendment with MIT is that the money flowing from MNTA to MIT is changed from a percent of net sales to a percent of the actual cash that MNTA receives from NVS. If true, it would stand to reason that MIT gets more cash while the getting is good as sole generic, but their take would be smaller than previously agreed upon if TEVA is approved